{"id":123493,"date":"2021-11-29T16:07:09","date_gmt":"2021-11-29T16:07:09","guid":{"rendered":"https:\/\/fin2me.com\/?p=123493"},"modified":"2021-11-29T16:07:09","modified_gmt":"2021-11-29T16:07:09","slug":"global-markets-assess-threat-of-omicron-variant","status":"publish","type":"post","link":"https:\/\/fin2me.com\/markets\/global-markets-assess-threat-of-omicron-variant\/","title":{"rendered":"Global markets assess threat of Omicron variant"},"content":{"rendered":"

A version of this story first appeared in CNN Business’ Before the Bell newsletter. Not a subscriber? You can sign up <\/em>right here<\/em>. You can listen to an audio version of the newsletter by clicking the same link.<\/em><\/p>\n

London (CNN Business)<\/cite>Wall Street despises uncertainty. The less information investors have, the harder it is to make decisions about how to position for the future.<\/p>\n

Unfortunately, this is an example of peak ambiguity. Traders have been left in the lurch as the world rushes to respond to the discovery of the new Omicron variant of the coronavirus. And there’s unlikely to be much clarity in the coming days.
\n“We have to go through a couple of weeks yet of uncertainty,” Dr. Paul Burton, the chief medical officer for Moderna, told CNN’s Paula Reid on Sunday.<\/p>\n